News
PMCPA News
Press releases appear below, filter by date.
Merck Sharp & Dohme, Gilead Sciences Europe, Daiichi-Sankyo and Allergan have been named in advertisements for breaches of ABPI Code.
Press release: 25 September 2020
Pfizer and Bristol Myers Squibb, The Alliance, named in advertisements for breaches of the ABPI Code of Practice
Press release: 25 September 2020
PMCPA launches search for a new Chair of the Code of Practice Appeal Board
Press release: 05 August 2020
PMCPA issues additional draft working document to support the Consultation on the proposed 2021 ABPI Code of Practice for the Pharmaceutical Industry
Press release: 23 July 2020
Mr William Harbage QC, Chair of the Code of Practice Appeal Board
Press release: 14 July 2020
Otsuka Pharmaceuticals Europe Ltd and Indivior UK limited have been named in advertisements for breaches of the ABPI Code. In addition Otsuka Pharmaceuticals Europe Ltd and AstraZeneca have been publicly reprimanded
Press release: 25 June 2020
LAUNCH OF ABPI CONSULTATION ON PROPOSALS FOR THE ABPI CODE OF PRACTICE 2021
Press release: 19 June 2020
PMCPA COVID-19 update
Press release: 18 March 2020
Daiichi-Sankyo, GW Pharmaceuticals, Bayer plc, Proveca Ltd, Otsuka UK & Otsuka Europe named in advertisements for breach of the ABPI Code of Practice
Press release: 27 July 2019
MHRA Guidance - Updates to prescribing information for centrally approved products in the event of the UK leaving the EU with no deal
Press release: 10 April 2019
Novo Nordisk Limited, Eli Lilly and Company Limited, Grunenthal Ltd and Napp Pharmaceuticals Limited named in advertisements for breaches of the ABPI Code of Practice
Press release: 14 December 2010
Novo Nordisk Limited, Eli Lilly and Company Limited, Grünenthal Ltd and Napp Pharmaceuticals Limited have each breached the ABPI Code of Practice for the Pharmaceutical Industry.
Grunenthal Ltd and Vifor Pharma UK Limited named in advertisements for breaches of the ABPI Code of Practice
Press release: 06 July 2012
Grünenthal Ltd and Vifor Pharma UK Limited have each breached Clause 2 of the ABPI Code of Practice and are the subject of advertisements in the medical, pharmaceutical and nursing press. In addition, Grünenthal has been publicly reprimanded.